✉news HealthMedicine first seen 2 h ago, last 46 min ago, peak #18
Insilico Medicine reports 40% response rate for AI-designed cancer drug
Original: Insilico Medicine reports 40% ORR at 130 mg for Pan-TEAD inhibitor ISM6331 designed using generative AI in heavily pretreated mesothelioma at ESMO 2026
Insilico Medicine announced results for ISM6331, a pan-TEAD inhibitor designed using generative AI, at ESMO 2026. In heavily pretreated mesothelioma patients, the drug achieved a 40% objective response rate at the 130 mg dose. The data highlight growing interest in AI-discovered cancer therapies and offer a potential option for patients with limited remaining treatments.
Why now: The ESMO 2026 presentation of strong clinical results for an AI-designed drug is drawing attention from the oncology and biotech communities.
Insilico MedicineISM6331ESMO 2026mesothelioma
Rank over time, top of the chart is #1. 2 snapshots from 2 h ago to 46 min ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3786667